Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress ...

Niraparib significantly improved PFS and time without symptoms for women with advanced ovarian cancer who responded to ...

BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall ...

Even after Merck & Co.’s Keytruda has climbed to the top of the industry’s sales charts and racked up dozens of FDA-a | A Keytruda-based regimen has shown a statistically significant overall survival ...

Nicoletta Colombo, MD, PhD, of the University of Milan-Bicocca, discussed the rationale behind paclitaxel with bevacizumab ...

The FDA has granted fast track designation to JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC), for the ...

Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda prove to ...

When pembrolizumab was added to paclitaxel with or without bevacizumab in platinum-resistant ovarian cancer, significant ...

The researchers argue that the integration of explainable AI into clinical decision-making pipelines could reshape cancer ...

A test in the Triad that can tell if you have an increased chance of breast cancer, ovarian cancer, colon cancer and heart ...

Akeso, Inc. (($HK:9926)) announced an update on their ongoing clinical study. Akeso, Inc. is conducting an exploratory, multi-cohort Phase II ...

"There was a time we paid for blood tests, only to come back days later, and the nurses said the results could not be traced.